Hypothesis

Senescent fibroblasts secrete both soluble SASP factors and matricrine‑rich extracellular vesicles that together dictate the regenerative quality of the tissue microenvironment. In acute injury, a transient senescence burst releases PDGF‑A‑containing vesicles that promote myofibroblast differentiation while simultaneously depositing a soluble fibronectin‑EDA isoform that keeps the matrix compliant. When senescence becomes chronic, the same cells shift vesicle cargo toward lysyl oxidase (LOX)–loaded exosomes and shed a cleaved, stiffening fibronectin fragment, tipping the balance toward fibrosis and inflammaging.

Mechanistic Basis

• Vesicle‑mediated matricrine delivery: Young senescent fibroblasts (p16^high, low SA‑β‑gal) enrich exosomes with PDGF‑A and intact fibronectin‑EDA, which integrates into the provisional matrix and supports progenitor anchorage without excessive crosslinking [https://pmc.ncbi.nlm.nih.gov/articles/PMC4349629/].
• SASP‑matrix crosstalk: The soluble SASP (IL‑6, TGFβ) recruits anti‑inflammatory macrophages that clear senescent cells [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00773/full]. In parallel, vesicle‑bound fibronectin‑EDA binds integrin α5β1 on macrophages, skewing them toward an M2 phenotype that secretes MMP‑2/9 to remodel matrix.
• Age‑dependent switch: With aging, mitochondrial dysfunction in senescent cells increases ROS‑dependent LOX loading into exosomes [https://doi.org/10.1101/2025.06.08.658533]. LOX crosslinks fibronectin‑EDA fragments, generating a stiff, pro‑fibrotic niche that impairs stem‑cell differentiation and sustains NF‑κB signaling in neighboring cells.

Predictions & Experimental Design

1. Vesicle cargo shift: Isolate exosomes from senescent fibroblasts harvested from young (2‑month) versus aged (24‑month) mice after standardized skin wound. Quantify PDGF‑A, intact fibronectin‑EDA, LOX, and cleaved fibronectin fragments by western blot and ELISA. Prediction: Young senescent exosomes are PDGF‑A^high/LOX^low; aged exosomes show the inverse.
2. Functional rescue: Treat aged wounded skin with young‑senescent‑derived exosomes (or recombinant PDGF‑A‑laden vesicles) and assess healing rate, collagen deposition, and macrophage phenotype. Prediction: Exosome treatment restores rapid closure and reduces α‑SMA^+ myofibroblast hyperaccumulation.
3. LOX inhibition: Apply LOX inhibitor (β‑aminopropionitrile) to aged wounds and measure exosome LOX activity, matrix stiffness (AFM), and senescence marker persistence. Prediction: LOX inhibition preserves exosome‑mediated PDGF‑A signaling while preventing matrix stiffening, improving regeneration without increasing senescent cell numbers.
4. In vivo lineage tracing: Use p16‑3MR mice crossed with a CD63‑GFP reporter to track vesicle release from senescent cells during acute versus chronic injury. Prediction: GFP^+ vesicles colocalize with PDGF‑A in early wounds and with LOX in late‑stage diabetic ulcers.

Potential Implications

If validated, this model reframes senolytics not as blanket senescent‑cell removal but as timed modulators of vesicle cargo. Senomorphic strategies that inhibit LOX loading or supplement PDGF‑A‑rich vesicles could preserve the chaperone function of senescence while blocking its fibrotic turn, offering a precision approach to age‑related tissue decline.